GlassScriptPhysician profile
Ajay Kumar Ajmani
NPI 1811998867
$6,319.41
in general payments reported to CMS, 2019-2025
47 companies · $501 in 2025
The $501 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,018 · 2020: $903 · 2021: $1,019 · 2022: $1,138 · 2023: $815 · 2024: $925 · 2025: $501.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,241.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,241.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $839.86 | 2019-2025 | Ozempic, Rybelsus |
| Amgen INC. | $708.02 | 2019-2025 | Enbrel, Otezla, Tavneos |
| Janssen Biotech, INC. | $453.53 | 2019-2024 | Tremfya |
| Astrazeneca Pharmaceuticals LP | $447.06 | 2019-2025 | Airsupra |
| Pfizer INC. | $409.44 | 2019-2025 | |
| Abbvie INC. | $338.94 | 2019-2024 | Rinvoq, Vraylar |
| Indivior INC. | $316.81 | 2019-2025 | Sublocade |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $306.05 | 2019-2024 | Xifaxan, Trulance |
| Ucb, INC. | $281.86 | 2019-2024 | Cimzia |
| Mallinckrodt Hospital Products INC. | $280.64 | 2021-2023 | Acthar |
| Supernus Pharmaceuticals, INC. | $208.02 | 2020 | |
| Novartis Pharmaceuticals Corporation | $184.96 | 2019-2024 | |
| Melinta Therapeutics, LLC | $180.09 | 2019-2022 | |
| Fresenius Kabi USA, LLC | $155.08 | 2024 | Idacio, Tyenne |
| Otsuka America Pharmaceutical, INC. | $106.96 | 2021-2025 | Rexulti, Nuedexta |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ajay Ajmani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.